Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
111. |
ECCT/24/05/03 | SIBP-MMR-02 A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age |
Principal Investigator(s) 1. Dr Walter Otieno 2. Dr. Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. Victoria Biomedical Research Institute (Kisumu county) |
27-05-2024 |
View |
112. |
ECCT/24/05/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county) |
08-05-2024 |
View |
113. |
ECCT/24/05/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county) |
08-05-2024 |
View |
114. |
ECCT/24/04/08 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Wilson Muraya Site(s) in Kenya 1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county) |
08-05-2024 |
View |
115. |
ECCT/24/04/07 | FORMATIVE-PEARLS TRIAL PEARLS FORMATIVE (Preventing pre-eclampsia: Evaluating AspiRin Low-dose regimens following risk Screening) |
Principal Investigator(s) 1. Zahida Qureshi 2. Alfred Osoti 3. George Gwako 4. Rosa Chemwey Site(s) in Kenya 1. Kakamega General County Teaching and Referral Hospital (Kakamega county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Kiambu Level 5 Hospital (Kiambu county) 4. Kisii Teaching and Referral Hospital (Kisii county) 5. Meru Teaching and Referral Hospital (Meru county) |
05-07-2024 |
View |
116. |
ECCT/24/04/06 | REACH 2 Realizing Effectiveness Across Continents with Hydroxyurea (REACH): A Phase I/II Prospective Trial of Hydroxyurea for Children and Young Adults with Sickle Cell Anaemia |
Principal Investigator(s) 1. Thomas Williams 2. Russell Ware Site(s) in Kenya Kilifi County Referal Hospital |
28-06-2024 |
View |
117. |
ECCT/24/04/05 | Phase III Vitiligo Study A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB- UVB Light Alone in the Treatment of Vitiligo |
Principal Investigator(s) 1. Dr. Hannah Wanyika Wanyika Site(s) in Kenya Kenyatta National Hospital - |
30-08-2024 |
View |
118. |
ECCT/24/04/04 | TNBC A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya 1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county) 2. International Cancer Institute (Nandi county) 3. The Aga Khan University Hospital - Kenya (Nairobi City county) |
19-09-2024 |
View |
119. |
ECCT/24/04/03 | SMAART-MAP trial Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform trial |
Principal Investigator(s) 1. Prof Kathryn Maitland Maitland Site(s) in Kenya Kilifi County Hospital |
29-08-2024 |
View |
120. |
ECCT/24/04/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Fredrick Kipyego Sawe Site(s) in Kenya 1. Walter Reed Army Institute of Research -Kericho Site (Kericho county) |
03-07-2024 |
View |